Incretin-based therapy and the quest for sustained improvements in β-cell health.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. High fat diet remodels the gene regulatory networks in the preoptic area.Scientific reports · 2026
   Article
2. Incretin - based therapy in diabetes mellitus: present scenario and expanding horizons.Nepal journal of epidemiology · 2016
   Article
3. Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug.PloS one · 2015
   Article
4. Effects of exenatide in a morbidly obese patient with type 2 diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2014
   Article
5. Biochemical Investigation of Inhibitory Activities of Plant-Derived Bioactive Compounds Against Carbohydrate and Glucagon-Like Peptide-1 Metabolizing Enzymes.Dose-response : a publication of International Hormesis Society
   Article

Corrections and comments

• Comment on
  Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as